Top Researchers Gather for the 15th ATTD Conference
Leading researchers gathered, in person, for the annual meeting of the ATTD Conference (April 27-30), featuring 30+ studies presented by…
ATTD Conference Brings Together Top Minds in Diabetes Research
Diabetes researchers from all over the world gather for the ATTD Conference, which will take place in-person and online from…
100, 100: Breakthrough T1D Research Leads to a New Class of Glucose-Lowering Agents
You’ve seen the ads: Victoza®. Ozempic®. Trulicity®. But did you know that these drugs came about, in part, because of…
FDA Approval of Senseonics Eversense® CGM for Use for Up to 6 Months
FDA approves Senseonics Eversense® E3, the first long-term implantable CGM system, and the E3 includes technology that extends the use…
100 Years, 100 Breakthrough T1D Scientists: The BB Rat—An Animal Model of Type 1 Diabetes
In 1974, a colony of non-diabetic BB rats develops diabetes. Examination of their pancreases revealed that they had no beta…
Interview with our New Community Screening and Clinical Trial Education Director
Breakthrough T1D has a new community screening and clinical trials education director. She's been a volunteer and now staff since…
Insulin: A Story of Innovation
On January 11, 1922—100 years ago—14-year-old Leonard Thompson, who was diagnosed with diabetes 3 years earlier, became the first person…
Stem Cell Replacement Therapy: Its Time has Begun
ViaCyte has results on its second stem cell-based technology, providing evidence of stem cells secreting insulin in response to meal…
Progress Toward Cures: Thoughts at Year’s End from Breakthrough T1D’s CEO
Breakthrough T1D CEO Aaron Kowalski, Ph.D., weighs in on the exciting news surrounding stem cell-derived beta cell replacement therapies, now…
First-in-Human Gene-Edited Stem Cell Trial? Check.
ViaCyte, a beta cell replacement company long supported by Breakthrough T1D, and CRISPR Therapeutics have a new first: Gene-editing for…
